Other

Novartis Q4 net profit rises to $2.0 billion

Swiss drug maker Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs.

Other

Pfizer's 4Q net plunges on charges, sales decline

Drugmaker Pfizer said Tuesday that fourth-quarter profit plunged 59 percent because of discontinued operations, restructuring and other charges, and generic competition continuing to siphon off revenue from former blockbuster ...

Other

Merck 3Q net income falls on charges, lower sales

Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges. It still beat Wall Street's ...

Other

Amgen 3Q profit jumps 24 pct. on stronger sales

Biotech drugmaker Amgen Inc. said Tuesday that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits.

Other

Novartis lifts sales outlook despite Q2 profit dip

(AP)—Swiss pharmaceutical company Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter.

Other

Pfizer Q1 profit up, but drugmaker cuts outlook

Pfizer Inc.'s first-quarter net income rose 53 percent despite falling sales, mainly because the world's second-largest drugmaker took big charges a year ago. Pfizer's results fell short of Wall Street's expectations, and ...

Medications

Bayer profits up 11.5 percent on new drugs

German chemical and pharmaceutical company Bayer AG said Thursday that its net profit rose 11.5 percent in the first quarter as new drugs, led by blood thinner Xarelto, boosted sales.

Medications

AstraZeneca reorg to cut 1,600 jobs in US, UK

(AP)—Struggling Anglo-Swedish drugmaker AstraZeneca PLC said Monday that it will eliminate 1,600 jobs, mostly in the U.S. and United Kingdom, as its new CEO starts a major research and development reorganization.

page 2 from 3